Azitra, Inc. Announces Purchase Agreement with Institutional Investor(s)

BRANFORD, Conn. , Feb. 4, 2025 /PRNewswire/ — Azitra, Inc. (NYSE American: AZTR),

a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with certain institutional investor(s) to purchase 3,339,300 shares of common stock at an offering price of $0.2785 per share, in a registered direct offering.

This latest development signifies a major milestone for Azitra, Inc. as they continue to make strides in the field of precision dermatology. The agreement with these institutional investors will provide the company with the necessary funds to further advance their research and development efforts, ultimately leading to the creation of groundbreaking therapies for various dermatological conditions.

Azitra, Inc.’s focus on precision dermatology sets them apart from other biopharmaceutical companies, as they strive to tailor their treatments to each individual patient’s specific needs. By harnessing the power of precision medicine, Azitra, Inc. aims to revolutionize the way dermatological conditions are treated, offering patients more effective and personalized solutions.

This securities purchase agreement is a testament to the confidence that institutional investors have in Azitra, Inc.’s innovative approach to dermatology. With this influx of capital, the company is well-positioned to bring their cutting-edge therapies to market, potentially changing the lives of millions of individuals suffering from skin conditions.

Impact on Individuals:

For individuals, this announcement from Azitra, Inc. could mean access to groundbreaking treatments for skin conditions that were previously difficult to manage. The company’s focus on precision dermatology ensures that patients receive personalized care that is tailored to their unique needs, potentially leading to better outcomes and improved quality of life.

Impact on the World:

On a larger scale, Azitra, Inc.’s advancements in precision dermatology have the potential to impact the world by revolutionizing the way dermatological conditions are treated. By offering more effective and personalized solutions, the company could set a new standard for dermatology care, ultimately improving the lives of individuals worldwide.

Conclusion:

In conclusion, Azitra, Inc.’s securities purchase agreement is a significant step forward for the company and the field of precision dermatology as a whole. With the support of institutional investors, Azitra, Inc. is poised to bring revolutionary therapies to market, potentially changing the landscape of dermatology care for the better. Individuals stand to benefit from personalized treatments, while the world at large could see improvements in dermatological care on a global scale.